4.07
price down icon4.38%   -0.15
after-market アフターアワーズ: 4.06 -0.01 -0.25%
loading
前日終値:
$4.22
開ける:
$4.21
24時間の取引高:
551.87K
Relative Volume:
0.55
時価総額:
$259.04M
収益:
$157.08M
当期純損益:
$-70.36M
株価収益率:
-3.6614
EPS:
-1.1116
ネットキャッシュフロー:
$-71.69M
1週間 パフォーマンス:
-1.10%
1か月 パフォーマンス:
-10.13%
6か月 パフォーマンス:
+137.35%
1年 パフォーマンス:
+155.38%
1日の値動き範囲:
Value
$4.005
$4.30
1週間の範囲:
Value
$3.785
$4.3091
52週間の値動き範囲:
Value
$1.29
$5.08

Macrogenics Inc Stock (MGNX) Company Profile

Name
名前
Macrogenics Inc
Name
セクター
Healthcare (1089)
Name
電話
301-251-5172
Name
住所
9704 MEDICAL CENTER DRIVE, Rockville, MD
Name
職員
293
Name
Twitter
@macrogenics
Name
次回の収益日
2026-08-13
Name
最新のSEC提出書
Name
MGNX's Discussions on Twitter

Compare MGNX vs VRTX, REGN, ARGX, RVMD, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
MGNX icon
MGNX
Macrogenics Inc
4.07 268.58M 157.08M -70.36M -71.69M -1.1116
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
515.57 128.19B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
805.86 82.72B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
986.80 53.26B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
211.94 43.66B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
362.66 39.31B 5.76B 514.49M 1.10B 4.4813

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-10 アップグレード B. Riley Securities Neutral → Buy
2025-09-17 再開されました Barclays Overweight
2024-11-07 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2024-08-01 ダウングレード BTIG Research Buy → Neutral
2024-07-31 ダウングレード B. Riley Securities Buy → Neutral
2024-07-31 ダウングレード Guggenheim Buy → Neutral
2024-05-10 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-05-10 ダウングレード Stifel Buy → Hold
2024-05-10 ダウングレード TD Cowen Buy → Hold
2024-04-26 開始されました B. Riley Securities Buy
2024-04-09 アップグレード TD Cowen Hold → Buy
2024-03-04 繰り返されました BTIG Research Buy
2024-02-14 ダウングレード H.C. Wainwright Buy → Neutral
2023-12-20 アップグレード Citigroup Neutral → Buy
2023-11-07 アップグレード Guggenheim Neutral → Buy
2023-03-17 ダウングレード Guggenheim Buy → Neutral
2022-11-22 ダウングレード Cowen Outperform → Market Perform
2022-11-14 アップグレード BMO Capital Markets Market Perform → Outperform
2022-07-18 ダウングレード SMBC Nikko Outperform → Neutral
2022-07-11 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-05-04 ダウングレード Guggenheim Buy → Neutral
2022-02-28 アップグレード Citigroup Neutral → Buy
2022-02-11 開始されました BMO Capital Markets Outperform
2022-02-04 開始されました SMBC Nikko Outperform
2021-11-17 再開されました Guggenheim Buy
2021-10-19 開始されました JMP Securities Mkt Outperform
2021-10-15 再開されました BTIG Research Buy
2021-04-26 再開されました Credit Suisse Outperform
2021-03-12 アップグレード Barclays Underweight → Overweight
2020-12-22 再開されました H.C. Wainwright Buy
2020-08-03 ダウングレード Citigroup Buy → Neutral
2020-06-01 アップグレード Guggenheim Neutral → Buy
2020-05-26 繰り返されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Underweight
2019-12-19 開始されました Cantor Fitzgerald Overweight
2019-12-18 開始されました Cantor Fitzgerald Overweight
2019-11-21 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-11-20 再開されました Guggenheim Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Guggenheim Neutral
2019-02-07 アップグレード Citigroup Sell → Buy
2019-02-07 ダウングレード Wedbush Outperform → Neutral
2019-02-06 アップグレード Raymond James Underperform → Mkt Perform
2019-02-04 ダウングレード Citigroup Neutral → Sell
2018-12-10 ダウングレード Raymond James Outperform → Underperform
2018-09-10 再開されました BTIG Research Buy
2018-05-31 開始されました Evercore ISI Outperform
2018-03-05 開始されました H.C. Wainwright Buy
2017-03-31 開始されました Raymond James Outperform
すべてを表示

Macrogenics Inc (MGNX) 最新ニュース

pulisher
01:20 AM

MGNX Maintained by B. Riley Securities -- Price Target Raised to $11.00 - GuruFocus

01:20 AM
pulisher
07:57 AM

B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating - marketscreener.com

07:57 AM
pulisher
Aug 14, 2026

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance

Aug 14, 2026
pulisher
Aug 14, 2026

MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

MacroGenics Inc earnings missed by $1.02, revenue fell short of estimates - Investing.com Nigeria

Aug 14, 2026
pulisher
Aug 13, 2026

MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 13, 2026
pulisher
Aug 13, 2026

MacroGenics Q2 adj. EPS $(0.27) misses $(0.13) estimate; sales miss - scanx.trade

Aug 13, 2026
pulisher
Aug 13, 2026

MacroGenics: Q2 Earnings Snapshot - Yahoo Finance

Aug 13, 2026
pulisher
Aug 13, 2026

MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner - marketscreener.com

Aug 13, 2026
pulisher
Aug 13, 2026

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position - manilatimes.net

Aug 13, 2026
pulisher
Aug 13, 2026

Gilead exercises option for MacroGenics pre-clinical bispecific program - The Pharma Letter

Aug 13, 2026
pulisher
Aug 13, 2026

MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP - MarketBeat

Aug 13, 2026
pulisher
Aug 12, 2026

Gilead exercises option on MacroGenics bispecific program By Investing.com - Investing.com UK

Aug 12, 2026
pulisher
Aug 11, 2026

MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com South Africa

Aug 11, 2026
pulisher
Aug 11, 2026

MacroGenics stock rises on $10M Gilead option exercise - Investing.com

Aug 11, 2026
pulisher
Aug 11, 2026

Gilead exercises option on MacroGenics bispecific program - Investing.com

Aug 11, 2026
pulisher
Aug 11, 2026

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - manilatimes.net

Aug 11, 2026
pulisher
Aug 10, 2026

MacroGenics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView

Aug 10, 2026
pulisher
Aug 06, 2026

MacroGenics (MGNX) Projected to Release Earnings on Thursday - MarketBeat

Aug 06, 2026
pulisher
Aug 03, 2026

MGNX (NASDAQ: MGNX) holder files to sell 20,166 common shares under Rule 144 - stocktitan.net

Aug 03, 2026
pulisher
Aug 03, 2026

Bank of America (NYSE: BAC) reports 4.0% beneficial stake in MacroGenics (MGNX) - Stock Titan

Aug 03, 2026
pulisher
Jul 31, 2026

MacroGenics Inc (MGNX) Institutional Confidence - TradingKey

Jul 31, 2026
pulisher
Jul 29, 2026

BlackRock (MGNX holder) discloses 7.1% MacroGenics stake in Schedule 13G filing - Stock Titan

Jul 29, 2026
pulisher
Jul 27, 2026

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important (MGNX) - Seeking Alpha

Jul 27, 2026
pulisher
Jul 27, 2026

Citizens reiterates MacroGenics stock rating ahead of ESMO data - Investing.com

Jul 27, 2026
pulisher
Jul 27, 2026

Citizens reiterates MacroGenics stock rating ahead of ESMO data By Investing.com - Investing.com Canada

Jul 27, 2026
pulisher
Jul 26, 2026

MacroGenics Inc (MGNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

MacroGenics, Inc. Revenue Breakdown – NASDAQ:MGNX - TradingView

Jul 26, 2026
pulisher
Jul 26, 2026

MGNX|MacroGenics Inc|Price:3.700|Chg%:-0.310 - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

MacroGenics Inc (MGNX) Cash Flow - TradingKey

Jul 25, 2026
pulisher
Jul 24, 2026

MacroGenics, Inc. Revenue Breakdown – DUS:M55 - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

TradingKey - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

MacroGenics slips on trial data for lead asset (MGNX:NASDAQ) - Seeking Alpha

Jul 24, 2026
pulisher
Jul 24, 2026

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 - manilatimes.net

Jul 24, 2026
pulisher
Jul 23, 2026

MacroGenics’ MGC026 meets Phase 1 trial milestone in SCCHN - Investing.com

Jul 23, 2026
pulisher
Jul 23, 2026

MacroGenics (MGNX) Advances Phase 1 Study of MGC026 - GuruFocus

Jul 23, 2026
pulisher
Jul 23, 2026

MacroGenics’ MGC026 meets trial threshold in head and neck cancer By Investing.com - Investing.com Nigeria

Jul 23, 2026
pulisher
Jul 23, 2026

MacroGenics Advances MGC026 in Phase 1 Oncology Trial - TipRanks

Jul 23, 2026
pulisher
Jul 23, 2026

MacroGenics’ MGC026 meets trial threshold in head and neck cancer - Investing.com

Jul 23, 2026
pulisher
Jul 23, 2026

Entera Bio Leads Our Top 3 Penny Stocks To Consider - Sahm

Jul 23, 2026
pulisher
Jul 23, 2026

MGNX stock holds focus as MacroGenics plans and pipeline metrics matter - Ad-hoc-news.de

Jul 23, 2026
pulisher
Jul 20, 2026

MacroGenics (MGNX): Millennium group discloses 3.7% beneficial stake in amended 13G - Stock Titan

Jul 20, 2026
pulisher
Jul 17, 2026

MacroGenics stock gains after FDA priority review as revenue rises and cash runway extends - Ad-hoc-news.de

Jul 17, 2026
pulisher
Jul 17, 2026

MacroGenics Inc (NASDAQ: MGNX) Share Price, MGNX Stock News, MGNX Share Price & Updates - Kalkine

Jul 17, 2026
pulisher
Jul 13, 2026

[144] MACROGENICS INC SEC Filing - Stock Titan

Jul 13, 2026
pulisher
Jul 13, 2026

Form 144 MACROGENICS For: 13 July By Investing.com - Investing.com Nigeria

Jul 13, 2026
pulisher
Jul 10, 2026

MacroGenics (MGNX) Short Interest & Short Float | Updated Jul 2026 - MarketBeat

Jul 10, 2026
pulisher
Jul 09, 2026

MGNX Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Pipeline DevelopmentOperating Margin Analysis - dars.gov.et

Jul 09, 2026

Macrogenics Inc (MGNX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$64.45
price up icon 2.20%
$36.23
price down icon 0.07%
$59.46
price up icon 1.21%
$128.31
price up icon 3.20%
$224.60
price down icon 1.62%
ONC ONC
$362.66
price up icon 4.27%
大文字化:     |  ボリューム (24 時間):